These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32401377)

  • 1. Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study.
    Dattola A; Balato A; Megna M; Gisondi P; Girolomoni G; De Simone C; Caldarola G; Cama E; Piaserico S; Fargnoli MC; Fidanza R; Parodi A; Burlando M; Offidani A; Diotallevi F; Potenza C; Conti A; Chiricozzi A; Campione E; Bianchi L
    J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2839-2845. PubMed ID: 32401377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of certolizumab pegol in naïve versus multi-treated patients affected by psoriatic arthritis.
    Dattola A; Vollono L; Cannizzaro MV; Caposiena Caro RD; Mazzilli S; Melino G; Candi E; Campione E; Bianchi L
    Ital J Dermatol Venerol; 2021 Aug; 156(4):434-439. PubMed ID: 33034437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
    Cauza E; Spak M; Cauza K; Hanusch-Enserer U; Dunky A; Wagner E
    Rheumatol Int; 2002 Nov; 22(6):227-32. PubMed ID: 12426660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of certolizumab pegol in cutaneous symptoms on psoriasis in patients with psoriatic arthritis: A retrospective analysis in real life.
    Dattola A; Mazzeo M; Di Stefano F; Manfreda V; Vollono L; Di Raimondo C; Di Matteo E; Bianchi L
    Dermatol Ther; 2020 May; 33(3):e13409. PubMed ID: 32291887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis.
    Chandran V; Gottlieb A; Cook RJ; Duffin KC; Garg A; Helliwell P; Kavanaugh A; Krueger GG; Langley RG; Lynde C; McHugh N; Mease P; Olivieri I; Rahman P; Rosen CF; Salvarani C; Thaci D; Toloza SM; Wong MY; Zhou QM; Gladman DD
    Arthritis Rheum; 2009 Sep; 61(9):1235-42. PubMed ID: 19714610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol.
    Walsh JA; Arledge T; Nurminen T; Peterson L; Stark J
    J Rheumatol; 2018 Jul; 45(7):922-928. PubMed ID: 29717036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study.
    Sunar I; Ataman S; Nas K; Kilic E; Sargin B; Kasman SA; Alkan H; Sahin N; Cengiz G; Cuzdan N; Gezer IA; Keskin D; Mülkoğlu C; Resorlu H; Bal A; Duruöz MT; Küçükakkaş O; Yurdakul OV; Melikoglu MA; Aydın Y; Ayhan FF; Bodur H; Calis M; Capkın E; Devrimsel G; Gok K; Hizmetli S; Kamanlı A; Keskin Y; Kocabas H; Kutluk O; Şen N; Şendur OF; Tekeoğlu I; Tolu S; Toprak M; Tuncer T
    Rheumatol Int; 2020 Feb; 40(2):283-294. PubMed ID: 31773391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
    Chiricozzi A; Burlando M; Caldarola G; Conti A; Damiani G; De Simone C; Dini V; Malagoli P; Peccerillo F; Potenza C; Scala E; Skroza N; Balato A
    Am J Clin Dermatol; 2020 Jun; 21(3):441-447. PubMed ID: 31786732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data.
    Dattola A; Cannizzaro MV; Mazzeo M; Bianchi L
    Dermatol Ther (Heidelb); 2017 Dec; 7(4):485-492. PubMed ID: 29139035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H; Nakagawa H;
    J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Improvement in Skin and Nail Psoriasis in Bio-naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO-VIBRANT Study.
    Mease P; Elaine Husni M; Chakravarty SD; Kafka S; Parenti D; Kim L; Hung Lo K; Hsia EC; Kavanaugh A
    ACR Open Rheumatol; 2020 Nov; 2(11):640-647. PubMed ID: 33073933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study.
    Korotaeva TV; Loginova EY; Getiya TS; Nasonov EL
    Ter Arkh; 2018 May; 90(5):22-29. PubMed ID: 30701886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
    Kavanaugh A; McInnes I; Mease P; Krueger GG; Gladman D; Gomez-Reino J; Papp K; Zrubek J; Mudivarthy S; Mack M; Visvanathan S; Beutler A
    Arthritis Rheum; 2009 Apr; 60(4):976-86. PubMed ID: 19333944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis.
    Carubbi F; Fidanza R; Palmieri M; Ventura A; Tambone S; Cipriani P; Giacomelli R; Fargnoli MC
    J Dermatolog Treat; 2020 Nov; 31(7):692-697. PubMed ID: 30963798
    [No Abstract]   [Full Text] [Related]  

  • 19. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI).
    Mease PJ
    Arthritis Care Res (Hoboken); 2011 Nov; 63 Suppl 11():S64-85. PubMed ID: 22588772
    [No Abstract]   [Full Text] [Related]  

  • 20. Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 study.
    Nash P; Mease PJ; Kirkham B; Singhal A; Quebe-Fehling E; Pricop L; Gaillez C
    Clin Exp Rheumatol; 2022 May; 40(5):952-959. PubMed ID: 34494957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.